Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.
about
Progress and prospects: immune responses to viral vectorsSeasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism.Systematic evaluation of AAV vectors for liver directed gene transfer in murine models.An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8+ T cells in miceImproved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer.Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenzaReprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of CancerMuscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors.Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaquesReplicating and non-replicating viral vectors for vaccine developmentRobust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9.Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant.Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy.Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.AAV Vectors Vaccines Against Infectious Diseases.AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells.The complex and evolving story of T cell activation to AAV vector-encoded transgene products.Continuous CD8⁺ T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery.The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector.Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines.Antigen fusion with C3d3 augments or inhibits humoral immunity to AAV genetic vaccines in a transgene-dependent manner.Intradermal Immunization with rAAV1 Vector Induces Robust Memory CD8(+) T Cell Responses Independently of Transgene Expression in DCs.DOK7 gene therapy enhances motor activity and life span in ALS model mice.Regulatory and Exhausted T Cell Responses to AAV Capsid.Autoimmunity, recessive diseases, and gene replacement therapy.Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines.Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction.Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing.A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque.Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction.Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination.
P2860
Q28264531-E7771E3E-9EC8-48E8-99BD-C0709EACF6B3Q30410126-94DE1BAC-9C71-46EC-9378-C7CBDFE95D66Q33730427-018CE21C-861D-4247-92FD-43F7A97FC541Q35091621-02F0AA21-57DF-4047-AED2-C9446777ACB4Q35451204-87EFB029-1856-480B-A0B7-52561789EE93Q35720693-F0B4F03B-6E4E-41DC-8A6F-8379281A60CBQ35949356-78ED7BD3-E324-4FCB-B151-35D705B0ECFFQ36085709-4FAD6B4D-18E8-44FD-953F-9A7E85698A9DQ36114234-EE59AF82-ECA9-402A-ADCD-596780C35C6FQ36464587-CD3D557D-29A3-42B1-9E25-9158E65DFC67Q36757156-37AAA382-B200-45F9-9A1D-941DE2AE7D7BQ36851838-871CDCD5-AE46-442E-BDC3-FE9A53EC24D0Q37066228-97CE74DB-5A3D-4F68-975D-68AB0F26BE16Q37127246-7049C292-E044-4CF2-BA73-1A44F50CF1B2Q37498000-77F0033A-F2EB-4D92-ACD8-0B6A777D8790Q37690491-14ADB8DC-0639-44FE-8C05-5C2A9381D518Q37814051-D1A84F03-E598-4AF6-B5E1-2494A2F664C8Q38959186-9C34EC34-71BC-4DAD-A076-A99496BF056BQ39126011-4F50975B-3252-4A18-AF22-A6295B784BC5Q39240212-EF6CA346-DCE3-4322-9B5F-014F979628A3Q39771124-03A9A079-2F1E-4982-A3B9-A4153567AADEQ40117829-AA1991FB-4E8F-43D4-B9A2-7B3AE949DAB9Q40207108-D9C7324C-DFBC-4672-9D38-5AD7D3211625Q40282843-239A8B76-91BE-447D-8282-71D504DD4A47Q41197115-3DC1B5A5-4DB9-4F0A-8139-28F221E789CFQ42024301-06AB53EE-7E74-42E3-BB84-BD67B94E5731Q42186779-E101CB6E-9B5D-4EED-B635-840FE24CF4DBQ42408255-36EA94AF-8E10-469A-915F-6A56623A767AQ42690486-3BE30493-621A-4E03-9021-06F67CCD1077Q45868920-A0E7DB1E-CAA2-49E3-BC90-7322C2447BF9Q47705389-14753503-C76A-4620-B4ED-BA8DC4A323BF
P2860
Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Vaccines based on novel adeno- ...... CD8+ T-cell responses in mice.
@en
Vaccines based on novel adeno- ...... CD8+ T-cell responses in mice.
@nl
type
label
Vaccines based on novel adeno- ...... CD8+ T-cell responses in mice.
@en
Vaccines based on novel adeno- ...... CD8+ T-cell responses in mice.
@nl
prefLabel
Vaccines based on novel adeno- ...... CD8+ T-cell responses in mice.
@en
Vaccines based on novel adeno- ...... CD8+ T-cell responses in mice.
@nl
P2093
P2860
P356
P1433
P1476
Vaccines based on novel adeno- ...... CD8+ T-cell responses in mice.
@en
P2093
James M Wilson
Jianping Lin
Lauren Mays
P2860
P304
11840-11849
P356
10.1128/JVI.01253-07
P407
P577
2007-08-22T00:00:00Z